Touchlight announces development of a vaccine against COVID-19
Cancer Research UK, University of Southampton and Touchlight Genetics Partner to develop head and neck cancer vaccine
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Touchlights’s chairman to help lead UK COVID-19 vaccine effort
Touchlight appoints Dr. Helen Horton as Chief Research Officer
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.